University of Thessaly (UTH)
Συγκριτική μελέτη, σε μετεμμηνοπαυσιακές γυναίκες, της in vivo επίδρασης στο σύστημα των κυτταροκινών οστεοπροτεγερίνης-RANKL, φαρμακευτικών παραγόντων με διαφορετική δράση στο δίπολο οστεοκλάστης - οστεοβλάστης
Abstract
dc:descriptionRANKL-RANK-OPG system plays a crucial role in bone metabolism and constitutes a major research field during the last years. RANKL is expressed by preosteoblasts and stromal cells and binds to RANK, which is expressed by cells of the osteoclast lineage. RANKL induces differentiation and fusion of osteoclast precursor cells and stimulates the activity of the mature osteoclast. The effects of RANKL are counteracted by osteoprotegerin (OPG), a soluble neutralizing decoy receptor. Drugs that modify bone turnover are expected to influence the production of OPG and RANKL. We aimed to evaluate the changes of OPG and RANKL levels in circulation, following administration of drugs that affect bone metabolism through different mechanisms [action upon osteoblast: teriparatide (TPTD) and action upon osteoclast: risedronate (RIS)]. Seventy-four postmenopausal women with osteopenia or osteoporosis were included in the study. The women were divided into three groups (controls - RIS - TPTD). Serum levels of iPTH, OPG, RANKL, as well as markers of bone formation (PINP, total ALP) and resorption (CTX) were measured before, three and six months after treatment. Both TPTD and RIS administration was safe and well tolerated by the patients; as aconsequence, compliance was very satisfactory. Serum PINP and CTX remained unchanged during the six months ofthe study in the control group, decreased significantly in RIS-treated patients, reflecting suppression of bone turnover, while increased significantly in TPTD-treated patients, reflecting stimulation of bone turnover. Serum levels of OPG remained unchanged as compared to the control group. On the other hand, sRANKL levels were decreased significantly during the six months ofthe study in all three studied groups. The OPG / RANKL ratio, thought to reflect the net effect ofboth cytokines on osteoclast activity, increased gradually in all three groups, as a consequence of decreased sRANKL levels. The lack of changes in OPG and sRANKL levels in systematic circulation probably suggests different kinetics of these substances in circulation as compared to bone microenvironment; another explanation could be low sensitivity of the methods used to recognize such subtle changes. In concusion, our data suggest that neither serum OPG or sRANKL nor their ratio can substitute the established bone markers in the monitoring of anti-osteoporotic treatment response. Despite the prevailing aspect that bone resorption markers should be prefered in order to monitor antiresorptive treatment and bone formation markers in order to monitor osteoanabolic treatment, our data show that both serum PINP and CTX are reliable markers ofboth RIS and TPTD action in women with postmenopausal osteoporosis. Serum total ALP, a non-specific marker of low cost and wide availability, can be used as an alternative (as long as liver function is normal) for both agents in case a more sophisticated bone marker is not available for TPTD-treated women.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2008
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Anastasilakis, Athanasios
- Αναστασιλάκης, Αθανάσιος
Subjects
dc:subject × 8Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/33867